Breaking Finance News

Prothena (NASDAQ:PRTA) target price raised to $87.00, issued a report today by RBC Capital

Yesterday Prothena (NASDAQ:PRTA) traded 4.67% higher at $62.74. The company’s 50-day moving average is $59.39 and its 200-day moving average is $56.18. The last stock close price is up 16.88% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 136,187 shares of the stock were exchanged, down from an average trading volume of 291,070

Prothena (NASDAQ:PRTA) had its target price raised to $87.00 by RBC Capital in a report released 9/15/2017. The new target price indicates a possible upside of 0.39% based on the company's last stock close price.

Previously on 08/17/2017, Evercore ISI reported about Prothena (NASDAQ:PRTA) raised the target price from $0.00 to $83.00. At the time, this indicated a possible upside of 0.44%.

See Chart Below

Prothena (NASDAQ:PRTA)

Prothena has a 52 week low of $40.58 and a 52 week high of $69.53 PRTA’s total market value is presently $0.

A total of 7 analysts have released a research note on PRTA. Four analysts rating the company a strong buy, three analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $73.86.

More About Prothena (NASDAQ:PRTA)

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.